Search
for
Sort by
Research 481–510 of 1000+
- Hair Are the Rankings—5-α Reductase Inhibitors and Minoxidil in Male Androgenetic Alopecia
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Hair Growth in a Patient with Alopecia Areata on Tocilizumab
- 13777 The off-label use of spironolactone in female pattern hair loss
- Polycystic ovary syndrome in patients with hair thinning
- Hair and Nail Manifestations of Systemic Disease
- 0441 Systemic autoimmune comorbidity in alopecia totalis and universalis compared with patchy alopecia areata: A retrospective cohort study
- 74643 Deuruxolitinib improves scalp hair regrowth over time in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- Liver Toxicity, a Rare Side Effect of Using Turmeric Supplements for Hair Loss
- A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
- 62339 Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- 61537 No Increased Risk of Breast or Gynecologic Cancers in Women with 5α-Reductase Inhibitor Exposure for Female Pattern Hair Loss: A Population-Based Propensity Score-Matched Cohort Study
- 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- 0350 Impact of switching janus kinase inhibitors in the treatment of severe alopecia areata
- Platelet-Rich Plasma for Androgenetic Alopecia: What the Dermatologist Needs to Know: Erratum
- M2 Macrophage and Extracellular Matrix Genes Are Enriched in High‐Activity Lichen Planopilaris
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
- 54306 Use of Music During Scalp Injections: A Preliminary Study
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
- 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib
- LB1029 The common fragrance, linalool, promotes core hair follicle pathology events associated with frontal fibrosing alopecia through activating a cognate olfactory receptor in the bulge
- 058 The pattern of Fas and Fas ligand expression in alopecia areata
- Association between hemoglobin A1c and the severity of androgenetic alopecia among female patients in a specialty alopecia clinic
- Efficacy of Low-Dose Spironolactone for Hair Loss in Women.
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2